Current Treatments
BETASERON® (interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis

AVONEX® (Interferon beta-1a) is a 166 amino acid glycoprotein with a predicted molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of AVONEX® is identical to that of natural human interferon beta.

COPAXONE is the brand name for glatiramer acetate (formerly known as copolymer-1). Glatiramer acetate, the active ingredient of COPAXONE, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000 – 9,000 daltons. Glatiramer acetate is identified by specific antibodies.

Rebif® (interferon beta-1a) is a purified 166 amino acid glycoprotein with a molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of Rebif® is identical to that of natural fibroblast derived human interferon beta. Natural interferon beta and interferon beta-1a (Rebif®) are glycosylated with each containing a single N-linked complex carbohydrate moiety.

Tysabri is a monoclonal antibody that affects the actions of the body's immune system. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. Tysabri is used to treat relapsing forms of multiple sclerosis. 		Gilenya™ is a new class of medication called a phingosine 1-phosphate receptormodulator, which is thought to act by retaining certain white blood cells (lympohcytes) in the lymph nodes, thereby preventing those cells from crossing the blood-brain barrier into the central nervous system (CNS). Preventing the entry of these cells into the CNS reduces inflammatory damage to nerve cells.

Early Symptoms
The most common early symptoms of MS include:
* Tingling * Numbness
* Loss of balance
* Weakness in one or more limbs
* Blurred or double vision

Less common symptoms of MS may include
* Slurred speech
* Sudden onset of paralysis
* Lack of coordination
* Cognitive difficulties
Listed above, the early symptoms. I tend to be a poster child for these. The symptoms that occur later on are too numerous just to list. There will be a link included that will get you to a site where these symptoms are listed and explained. Keep in mind that someone may have some of these or many of these, there is no way to tell.
Multiple sclerosis statistics show that approximately 250,000 to 350,000 people in the United States have been diagnosed with this disease. The life expectancy for people with multiple sclerosis is nearly the same as for those without MS. Because of this, multiple sclerosis statistics place the annual cost of MS in the United States in the billions of dollars. MS is five times more prevalent in temperate climates -- such as those found in the northern United States, Canada, and Europe -- than in tropical regions. Furthermore, the age of 15 seems to be significant in terms of risk for developing the disease. Some studies indicate that a person moving from a high-risk (temperate) to a low-risk (tropical) area before the age of 15 tends to adopt the risk (in this case, low) of the new area and vice versa. Other studies suggest that people moving after age 15 maintain the risk of the area where they grew up.

Tuesday, October 4, 2011

MSConnection Fall 2011

Table of Contents — Fall 2011 Issue

Passes For MS Logo
Passes for MS Campaign Gains Yardage for People with multiple sclerosis

Top Stories

From the President
Passes for MS Campaign Gains Yardage for People with multiple sclerosis
Annual Meeting of Members

News

Medicare “Improvement Standard” Challenged
Potential Anti-Spasticity Treatment Boosted by the Society’s Fast Forward Program
Welcome to Digital Momentum!
New Free App!
You’ll be seeing a lot more of this thing!
Judy Hallam Receives New Hampshire Governor’s Accessibility Award

Newly Diagnosed

The Benefits of Denial

Programs

Medical Student Fellowship
Regional Programs Offer Many Opportunities!
Program Highlights
Building a Life of Inclusion in Fall River

Research

Understanding CCSVI and MS
Resources to find Clinical Trials
MS NOW
Research News

Advocacy

MS Activist Blog
Action Alert
Government Relations Committee
Health Care Reform Implementation
Federal Update
Maine
Massachusetts
New Hampshire
Vermont

Volunteers

Passionate People = Productivity

Fundraising

Thank you to our sponsors!
The Golden Circle
Students conduct penny drive for MS
Ride to be Cool
Zumba
Cape Cod Getaway
NH Seacoast Escape
Bike MS Season Starts Strong!
Journey of Hope 2011
30th Annual MS Harborfest!
Fashion Plates Luncheon & Fashion Show
Boston Volvo 5K Road Race

Calendar of Events - see current calendar

Classified Ads - see current listings

Community Programs Catalog Fall 2011

Facebook Become a fan of the Greater New England Chapter on Facebook

You are receiving this email because you chose to subscribe electronically to the MS Connection. To update your email preferences, including unsubscribing from MS Connection, please click the Unsubscribe link below.

Early and ongoing treatment with an FDA-approved therapy can make a difference for people with multiple sclerosis. Learn about your options by talking to your health care professional and contacting the National MS Society at http://main.nationalmssociety.org/ or 1-800-FIGHT-MS (344-4867).

Our postal address is:
National Multiple Sclerosis Society
733 Third Avenue
New York, New York 10017
Posted by Steve at Tuesday, October 04, 2011

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

About Me

My photo
North Grafton, Massachusetts, United States
Well-educated, disabled at this point with Multiple Sclerosis. I am very glad that I was able to do the things that I have been able to do over the years. had to change the picture, this one's more realistic.